Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

Items 501–600 of 1,006

Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR
Burger, W. A. C., Pham, V., Vuckovic, Z., Powers, A. S., Mobbs, J. I., Laloudakis, Y. D., Glukhova, A., Wootten, D. L., Tobin, A. B., Sexton, P. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41199-5 · Cited by 39
Accelerated Pace of Aging in Schizophrenia: Five Case-Control Studies
Caspi, A., Shireby, G. L., Mill, J. S., Moffitt, T. E., Sugden, K., & Hannon, E. J. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.023 · Cited by 39
Annual Research Review: Threats to the validity of child psychiatry and psychology
Rutter, M. L., & Pickles, A. R. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12461 · Cited by 41
A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project
Bioque, M., LLerena, A., Cabrera, B., Mezquida, G., Lobo, A., González-Pinto, A. M., Díaz‐Caneja, C. M., Corripio, I., Aguilar, E. J., Bulbena, A., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv121 · Cited by 40
Betahistine decreases olanzapine-induced weight gain and somnolence in humans
Barak, N., Beck, Y., & Albeck, J. H. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115626349 · Cited by 39
Atypical antipsychotics and effects on feeding: from mice to men
Benarroch, L., Kowalchuk, C., Wilson, V. S., Teo, C., Guenette, M. D., Chintoh, A. F., Nesarajah, Y., Taylor, V. H., Selby, P. L., Fletcher, P. J., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4324-8 · Cited by 39
Negative affect predicts social functioning across schizophrenia and bipolar disorder: Findings from an integrated data analysis
Grove, T. B., Tso, I. F., Chun, J., Mueller, S. A., Taylor, S. F., Ellingrod, V. L., McInnis, M. G., & Deldin, P. J. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.06.031 · Cited by 39
Optimizing Research Payoff
Miller, J. O., & Ulrich, R. (2016) · Perspectives on Psychological Science · doi:10.1177/1745691616649170 · Cited by 41
Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations
Myles, N., Myles, H., Clark, S. R., Bird, R. J., & Siskind, D. J. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417720516 · Cited by 41
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness
Barnes, T. R. E., Leeson, V. C., Paton, C., Marston, L., Davies, L. M., William, W., Osborn, D., Kumar, R., Keown, P., Zafar, R., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21490 · Cited by 39
Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis
Hu, Q., Zhang, F., Teng, W., Hao, F., Zhang, J., Yin, M., & Wang, N. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8621-x · Cited by 39
Neural correlates of exercise training in individuals with schizophrenia and in healthy individuals: A systematic review
van der Stouwe, E. C. D., van Busschbach, J. T., de Vries, B., Cahn, W., Aleman, A., & Pijnenborg, G. H. M. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.04.018 · Cited by 43
Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment
Kamgar-Dayhoff, P., & Brelidze, T. I. (2021) · Oncotarget · doi:10.18632/oncotarget.28010 · Cited by 43
The impact of antipsychotics as a risk factor for thromboembolism
Ogłodek, E. A., Just, M. J., Grzesińska, A. D., Araszkiewicz, A. S., & Szromek, A. R. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.12.003 · Cited by 38
Emerging Roles of FTO in Neuropsychiatric Disorders
Chang, R., Huang, Z., Zhao, S., Zou, J., Li, Y., & Tan, S. (2022) · BioMed Research International · doi:10.1155/2022/2677312 · Cited by 39
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
Hart, X. M., Gründer, G., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Cumming, P. D., Frajerman, A., Hefner, G., Howes, O. D., et al. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2366235 · Cited by 39
Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia
Martin, A. K., & Mowry, B. J. (2015) · Psychological Medicine · doi:10.1017/s0033291715001701 · Cited by 38
Dementia praecox redux: A systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia
Rowe, A. R., Mercer, L., Casetti, V., Sendt, K.-V., Giaroli, G., Shergill, S. S., & Tracy, D. K. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114564096 · Cited by 41
A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal
Suzuki, T. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 40
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 40
Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness
Mentzel, C. L., Bakker, P. R., van Os, J., Drukker, M., Matroos, G. E., Hoek, H. W., Tijssen, M. A. J., & van Harten, P. N. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11049 · Cited by 38
Hyperprolactinaemia in first episode psychosis - A longitudinal assessment
Lally, J., Ajnakina, O., Stubbs, B., Williams, H. R., Colizzi, M., Carra, E., Fraietta, S., Gardner-Sood, P., Greenwood, K., Atakan, Z., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.037 · Cited by 38
Physical Health and Drug Safety in Individuals with Schizophrenia
Pringsheim, T. M., Kelly, M. A., Urness, D., Teehan, M. D., Ismail, Z., & Gardner, D. M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717719898 · Cited by 44
Benzisothiazol‐3‐ones through a Metal‐Free Intramolecular N–S Bond Formation
Yang, K., Zhang, H., Niu, B., Tang, T., & Ge, H. (2018) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201801090 · Cited by 38
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study
Smith, R. C., Maayan, L. A., Wu, R., Youssef, M., Jing, Z., Sershen, H. W., Szabo, V., Meyers, J., Jin, H., Zhao, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5079-1 · Cited by 38
Self-citation
Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine
Maideen, N. M. P. (2019) · World Journal of Pharmacology · doi:10.5497/wjp.v8.i2.14 · Cited by 37
Network pharmacology-based identification for therapeutic mechanism of Ling-Gui-Zhu-Gan decoction in the metabolic syndrome induced by antipsychotic drugs
Xiang, S.-Y., Zhao, J., Lu, Y., Chen, R.-M., Wang, Y., Chen, Y., Long, B., Zhu, L.-P., Yao, P.-F., Xu, Y.-F., et al. (2019) · Comput. Biol. Medicine · doi:10.1016/j.compbiomed.2019.05.007 · Cited by 30
Comparative efficacy of Chinese herbal injections for the treatment of community-acquired pneumonia: A Bayesian network meta-analysis of randomized controlled trials
Huang, X., Duan, X., Zhu, Y., Wang, K., Wu, J., & Tian, X. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.153009 · Cited by 38
Baseline structural and functional magnetic resonance imaging predicts early treatment response in schizophrenia with radiomics strategy
Cui, L., Fu, Y., Liu, L., Wei, Y., Wu, X., Xi, Y.-B., Wang, H.-N., Yin, H. J., & Yin, H. J. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15046 · Cited by 40
Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
Lintunen, J., Lähteenvuo, M., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.030 · Cited by 36
Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator
McEvoy, J. P., & Citrome, L. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mcci.010316 · Cited by 37
Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis
Miura, I., Zhang, J., Hagi, K., Lencz, T., Kane, J. M., Yabe, H., Malhotra, A. K., & Correll, C. U. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.06.002 · Cited by 37
Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study
Yeisen, R. A. H., Bjørnestad, J. R., Joa, I., Johannessen, J. O., & Opjordsmoen, S. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1425-9 · Cited by 36
Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents
Mogwitz, S., Buse, J., Wolff, N., & Roessner, V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00460 · Cited by 37
A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales
Roberts, R., Neasham, A., Lambrinudi, C., & Khan, A. (2018) · JRSM Open · doi:10.1177/2054270418758570 · Cited by 37
Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics
Minjon, L., van den Ban, E. F., de Jong, E., Souverein, P. C., Egberts, T. C. G., & Heerdink, E. R. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0139 · Cited by 37
Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
Lu, J., Yang, Y., Lü, J., Wang, Z., He, Y., Yan, Y., Fu, K., Jiang, W., Xu, Y., Wu, R., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-020-03034-9 · Cited by 37
Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia
Smith, R. L., Wollmann, B. M., Kyllesø, L., Tran, T. T. A., Tveito, M., & Molden, E. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001507 · Cited by 37
Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT
Gumley, A. I., Bradstreet, S., Ainsworth, J. D., Allan, S., Álvarez‐Jiménez, M., Birchwood, M. J., Briggs, A. H., Bucci, S., Cotton, S., Engel, L., et al. (2022) · Health Technology Assessment · doi:10.3310/hlze0479 · Cited by 41
Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice
Traut, J., Prius-Mengual, J., Meijer, E. J., McKillop, L. E., Alfonsa, H., Hoerder‐Suabedissen, A., Song, S. H., Fehér, K. D., Riemann, D. W., Molnár, Z., et al. (2023) · eLife · doi:10.7554/elife.84740 · Cited by 37
Association between antipsychotic-induced metabolic side-effects and clinical improvement: A review on the Evidence for “metabolic threshold”
Sharma, E., Rao, N. P., & Venkatasubramanian, G. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2013.11.017 · Cited by 37
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil
Citrome, L. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121809 · Cited by 37
Design, synthesis, and biological evaluation of fluorinated imidazo[1,2- a ]pyridine derivatives with potential antipsychotic activity
Marcinkowska, M., Kołaczkowski, M., Kamiński, K., Bucki, A., Pawłowski, M., Siwek, A., Karcz, T. P., Mordyl, B., Starowicz, G., Kubowicz, P., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.059 · Cited by 37
A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents
Krøigaard, S. M., Clemmensen, L., Tarp, S., & Pagsberg, A. K. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0140 · Cited by 39
Comparative effectiveness of antipsychotic treatment strategies for relapse prevention in first-episode schizophrenia in Finland: a population-based cohort study
Taipale, H. T., Tanskanen, A., Howes, O. D., Correll, C. U., Kane, J. M., & Tiihonen, J. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00366-3 · Cited by 38
Cortico-basal ganglia circuits involved in different motivation disorders in non-human primates
Sgambato, V., Worbe, Y., Epinat‐Duclos, J., Féger, J., & Tremblay, L. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0911-9 · Cited by 42
Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia
Pridan, S., Swartz, M., Baruch, Y., Tadger, S., Plopski, I., & Barak, Y. (2014) · International Psychogeriatrics · doi:10.1017/s1041610214001756 · Cited by 36
Weight change during long-term treatment with lurasidone
Meyer, J. M., Mao, Y., Pikalov, A., Cucchiaro, J. B., & Loebel, A. D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000091 · Cited by 36
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes
Mas, S., Gassó, P., Lafuente, A., Bioque, M., Lobo, A., González-Pinto, A. M., Olmeda, M. S., Corripio, I., LLerena, A., Cabrera, B., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.44 · Cited by 36
Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directions
Breitborde, N. J. K., Moe, A. M., Ered, A., Ellman, L. M., & Bell, E. K. (2017) · Psychology Research and Behavior Management · doi:10.2147/prbm.s111593 · Cited by 36
Sleep Disturbance as a Precursor of Severe Regression in Kleefstra Syndrome Suggests a Need for Firm and Rapid Pharmacological Treatment
Vermeulen, K., Staal, W., Janzing, J., van Bokhoven, H., Egger, J. I. M., & Kleefstra, T. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000226 · Cited by 36
Comparative efficacy of Chinese herbal injections for treating chronic heart failure: a network meta-analysis
Wang, K.-H., Wu, J., Zhang, D., Duan, X., & Ni, M. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2090-3 · Cited by 36
Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia
Sonnenschein, S. F., & Grace, A. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.009 · Cited by 37
Psychosis in Parkinson’s disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges
Waddington, J. L. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0373-y · Cited by 37
Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management
González-Rodríguez, A., Labad, J., & Seeman, M. V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109941 · Cited by 36
Akathisia and Newer Second‐Generation Antipsychotic Drugs: A Review of Current Evidence
Chow, C. L., Kadouh, N. K., Bostwick, J. R., & VandenBerg, A. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2404 · Cited by 36
Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study
Bioque, M., Parellada, E., García‐Rizo, C., Amoretti, S., Fortea, A., Oriolo, G., Palau, P., Boix-Quintana, E., Safont, G., & Bernardo, M. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2020.72 · Cited by 36
Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway
Li, R., Zhu, W., Huang, P., Yang, Y., Luo, F., Dai, W., Shen, L., Pei, W., & Huang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111803 · Cited by 36
Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis
Seppälä, A., Pylvänäinen, J., Lehtiniemi, H., Hirvonen, N., Corripio, I., Koponen, H., Seppälä, J., Ahmed, A. O., Isohanni, M. K., Miettunen, J., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.08.005 · Cited by 37
Schizophrenia
Hasan, A., Falkai, P., Lehmann, I., & Gäebel, W. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0412 · Cited by 37
Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent
Czopek, A., Kołaczkowski, M., Bucki, A., Byrtus, H., Pawłowski, M., Kazek, G., Bojarski, A. J., Piaskowska, A., Kalinowska‐Tłuścik, J., Partyka, A., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.026 · Cited by 36
An observational study of clozapine induced sedation and its pharmacological management
Perdigues, S. R., Sauras-Quetcuti, R. B., Mané, A., Mann, L., Mundell, C., & Fernández-Egea, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.006 · Cited by 36
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
de Bartolomeis, A., Ciccarelli, M., Vellucci, L., Fornaro, M., Iasevoli, F., & Barone, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2145884 · Cited by 38
Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel
Siskind, D. J., Northwood, K. S., Pillinger, T., Chan, S., Correll, C. U., Cotes, R. O., Every‐Palmer, S., Hahn, M., Howes, O. D., Kane, J. M., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00098-7 · Cited by 39
Cognitive enhancing agents in schizophrenia and bipolar disorder
Vreeker, A., van Bergen, A. H., & Kahn, R. S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.014 · Cited by 37
Do antipsychotics increase diabetes risk in children and adolescents?
Galling, B., & Correll, C. U. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.979150 · Cited by 37
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. U. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36
A Systematic Review on the Pharmacological Treatment of Delusional Disorder
Muñoz-Negro, J. E., & Cervilla, J. A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000595 · Cited by 35
Inverse association between negative symptoms and body mass index in chronic schizophrenia
Mezquida, G., Savulich, G., García‐Rizo, C., García‐Portilla, M. P., Toll, A., García-Álvarez, L., Bobes, J., Mané, A., Bernardo, M., & Fernández-Egea, E. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.002 · Cited by 37
Clozapine Use in a Cohort of First-Episode Psychosis
Doyle, R., Behan, C. L., O’Keeffe, D., Masterson, S., Kinsella, A., Kelly, A., Sheridan, A., Keating, D., Hynes-Ryan, C., Madigan, K. V., et al. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000734 · Cited by 35
Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
Kirino, E. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0166-y · Cited by 35
Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials
Kishi, T., Matsui, Y., Matsuda, Y., Katsuki, A., Hori, H., Yanagimoto, H., Sanada, K., Morita, K., Yoshimura, R., Shoji, Y., et al. (2018) · Pharmacopsychiatry · doi:10.1055/a-0574-0088 · Cited by 35
The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia
Sienaert, P. A., van Harten, P. N., & Rhebergen, D. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00025-3 · Cited by 38
The role of lumateperone in the treatment of schizophrenia
Syed, A. B., & Brašić, J. R. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034019 · Cited by 37
Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
Marder, S. R., Hakala, M., Josiassen, M. K., Zhang, P. G. Y., Ouyang, J., Weiller, E., Weiss, C., & Hobart, M. (2016) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.57 · Cited by 35
Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study
Ishigooka, J., Iwashita, S., & Tadori, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12654 · Cited by 35
A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics
Tanda, G., Valentini, V., De Luca, M. A., Perra, V., Serra, G. P., & Di Chiara, G. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3780-2 · Cited by 33
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 33
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia
Kołaczkowski, M., Marcinkowska, M., Bucki, A., Śniecikowska, J., Pawłowski, M., Kazek, G., Siwek, A., Jastrzębska‐Więsek, M., Partyka, A., Wasik, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.045 · Cited by 34
Genetic and Clinical Factors Affecting Plasma Clozapine Concentration
Olsson, E., Edman, G., Bertilsson, L., Hukic, D. S., Lavebratt, C., Eriksson, S. V., & Ösby, U. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01704 · Cited by 34
Retracted: A meta‐analysis and theoretical critique of oxytocin and psychosis: Prospects for attachment and compassion in promoting recovery
Gumley, A. I., Braehler, C., & MacBeth, A. M. (2014) · British Journal of Clinical Psychology · doi:10.1111/bjc.12041 · Cited by 34
Retracted
What are the top 10 physical activity research questions in schizophrenia?
Vancampfort, D., Rosenbaum, S., Probst, M., Connaughton, J., du Plessis, C., Yamamoto, T., & Stubbs, B. (2016) · Disability and Rehabilitation · doi:10.3109/09638288.2015.1116622 · Cited by 35
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment
Juncal‐Ruíz, M., Ramírez-Bonilla, M., Gómez-Arnau, J., de la Foz, V. O., Suárez‐Pinilla, P., Martínez‐García, O., Neergaard, K. D., Tabarés‐Seisdedos, R., & Crespo‐Facorro, B. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4646-1 · Cited by 34
A simple model to solve a complex drug toxicity problem
Dixit, V. A. (2018) · Toxicology Research · doi:10.1039/c8tx00261d · Cited by 34
Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia
Olmos, I., Ibarra, M., Vázquez, M., Maldonado, C., Fagiolino, P. L., & Giachetto, G. (2019) · BioMed Research International · doi:10.1155/2019/3163502 · Cited by 34
Altered levels of immune cell adhesion molecules are associated with memory impairment in schizophrenia and healthy controls
Cai, H. Q., Weickert, T. W., Catts, V. S., Balzan, R. P., Galletly, C. A., Liu, D., O׳Donnell, M., & Weickert, C. S. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.06.017 · Cited by 34
Cardiometabolic risk prediction algorithms for young people with psychosis: a systematic review and exploratory analysis
Perry, B. I., Upthegrove, R., Crawford, O., Jang, S.-H., Lau, E., McGill, I., Carver, E., Jones, P. B., & Khandaker, G. M. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13212 · Cited by 36
Management of Tardive Syndrome: Medications and Surgical Treatments
Factor, S. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00898-3 · Cited by 37
Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses
Perry, B. I., Bowker, N., Burgess, S., Wareham, N. J., Upthegrove, R., Jones, P. B., Langenberg, C., & Khandaker, G. M. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac001 · Cited by 36
Lumateperone for the Treatment of Schizophrenia
Edinoff, A. N., Wu, N. W., deBoisblanc, C., Feltner, C. O., Norder, M., Tzoneva, V., Kaye, A. M., Cornett, E. M., Kaye, A. D., Viswanath, O., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4372 · Cited by 38
Decisions on WHO's essential medicines need more scrutiny
Barbui, C., & Purgato, M. (2014) · BMJ · doi:10.1136/bmj.g4798 · Cited by 34
Self-citation
Clinical management of comorbid diabetes and psychotic disorders
Chwastiak, L., Freudenreich, O., Tek, C., McKibbin, C. L., Han, J., McCarron, R. M., & Wisse, B. E. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00105-4 · Cited by 36
Phenothiazines and their Evolving Roles in Clinical Practice: A Narrative Review
Edinoff, A. N., Armistead, G., Rosa, C. A., Anderson, A., Patil, R., Cornett, E. M., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.38930 · Cited by 36
Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis
Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35
Second generation antipsychotics in ‘real-life’ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch
Rafaniello, C., Pozzi, M., Pisano, S., Ferrajolo, C., Bertella, S., Sportiello, L., Carnovale, C., Sullo, M. G., Cattaneo, D., Gentili, M., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1229301 · Cited by 33
Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states
Sgambato, V., & Tremblay, L. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1693-z · Cited by 37
Challenges and opportunities for the development of new antipsychotic drugs
Forray, C., & Buller, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.05.009 · Cited by 34
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo
Ballon, J. S., Pajvani, U. B., Mayer, L., Freyberg, Z., Freyberg, R. J., Contreras, I., ROSENBAUM, M. S., Leibel, R. L., & Lieberman, J. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754708 · Cited by 33
Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
Barbosa, W. B., Costa, J. D. O., de Lemos, L. L. P., Gomes, R. M., de Oliveira, H. N., Ruas, C. M., Acúrcio, F. D. A., Barbui, C., Bennie, M., Godman, B., et al. (2018) · Applied Health Economics and Health Policy · doi:10.1007/s40258-018-0408-4 · Cited by 34
Self-citation
Capturing behavioral indicators of persecutory ideation using mobile technology
Buck, B., Hallgren, K. A., Scherer, E. A., Brian, R., Wang, R., Wang, W., Campbell, A. T., Choudhury, T., Hauser, M., Kane, J. M., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.06.002 · Cited by 32

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks